Kenya - English - Pharmacy and Poisons Board

fortified procaine penicillin b.p 4mu - injection - fortified procaine penicillin b.p 4mu - procaine benzylpenicillin

Spain - English - HMA (Heads of Medicines Agencies)

fort dodge veterinaria s.a. - butorphanol 10 mg/ml - solution for injection - horses food - butorphanol

France - English - HMA (Heads of Medicines Agencies)

fort dodge veterinaria s.a. - butorphanol 10 mg/ml - solution for injection - horses food - butorphanol

European Union - English - EMA (European Medicines Agency)

astrazeneca ab - nirsevimab - immune sera and immunoglobulins, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season.beyfortus should be used in accordance with official recommendations.

United States - English - NLM (National Library of Medicine)

teligent pharma, inc. - ceftazidime (unii: 9m416z9qnr) (ceftazidime anhydrous - unii:dzr1ent301) - ceftazidime anhydrous 200 mg in 1 ml - fortaz is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: fortaz may be used alone in cases of confirmed or suspected sepsis. ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. fortaz may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. when such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. the dose depends on the severity of the infection and the patient's condition. to reduce the development of drug-resistant bacteria and maintain the effectiveness of fortaz and other antibacterial drugs, fortaz should be used only to treat infections that are proven or strongly suspected

United States - English - NLM (National Library of Medicine)

teligent pharma, inc. - ceftazidime (unii: 9m416z9qnr) (ceftazidime anhydrous - unii:dzr1ent301) - fortaz is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: fortaz may be used alone in cases of confirmed or suspected sepsis. ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. fortaz may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. when such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. the dose depends on the severity of the infection and the patient's condition. to reduce the development of drug-resistant bacteria and maintain the effectiveness of fortaz and other antibacterial drugs, fortaz should be used only to treat infections that are proven or strongly suspected

Israel - English - Ministry of Health

astellas pharma international b.v., israel - enfortumab vedotin - powder for concentrate for solution for infusion - enfortumab vedotin 20 mg/vial - enfortumab vedotin - padcev is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (muc) who: - have previously received a programmed death receptor-1 (pd-1) or programmed death-ligand 1 (pd-l1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting or:- are ineligible for cisplatin-containing chemotherapy and have previously received a pd-1/pd-l1 inhibitor.

Israel - English - Ministry of Health

astellas pharma international b.v., israel - enfortumab vedotin - powder for concentrate for solution for infusion - enfortumab vedotin 30 mg/vial - enfortumab vedotin - padcev is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (muc) who: - have previously received a programmed death receptor-1 (pd-1) or programmed death-ligand 1 (pd-l1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting or:- are ineligible for cisplatin-containing chemotherapy and have previously received a pd-1/pd-l1 inhibitor.

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - enfortumab vedotin, quantity: 30 mg - injection, powder for - excipient ingredients: polysorbate 20; histidine hydrochloride monohydrate; histidine; trehalose dihydrate - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand-1 inhibitor.

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - enfortumab vedotin, quantity: 20 mg - injection, powder for - excipient ingredients: polysorbate 20; trehalose dihydrate; histidine; histidine hydrochloride monohydrate - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand-1 inhibitor.